Canine viral hepatitis (formerly called Rubarth’s disease) is caused by a virus, canine adenovirus Type 1 (CAV-1). In Europe, it affects primarily dogs and foxes.
The main source of infection is by ingesting the urine, faeces or saliva of infected dogs. Recovered dogs may shed virus in their urine for up to one year.
The virus is resistant to many disinfectants, and can persist in the environment for weeks or months. Dogs are most commonly infected by virus left surviving in the environment rather than direct ‘dog to dog’ contact.
Very young puppies can die quickly, and in a kennel situation, spread can be rapid.
The infection gains entry via the mouth, throat and tonsils, before spreading and affecting other organs, especially the liver. Death is common, even with treatment.
Symptoms can vary from very mild to sudden death. Importantly, vaccination has greatly reduced the incidence of this disease in the UK.
Hyperacute form (in young puppies)
Puppies under 3 weeks may show sudden abdominal pain, with death occurring within a few hours. This form is rarely seen nowadays.
Acute form (classic disease)
Early cases are often characterised by marked lethargy. On examination, dogs have a high temperature, inflammation of the tonsils (tonsillitis) and enlarged lymph glands below the jaw. Acute tonsillitis is not common in dogs, and should arouse strong suspicions.
Vomiting and/or diarrhoea often then develops and the dog will lose it’s appetite. Some dogs may find bright light painful.
The liver is painful and enlarged on palpation. Jaundice and bleeding from the gums may develop as the liver fails. At this stage, the mucous membranes become pale or jaundiced. The dog has a tucked up appearance due to the pain, and about 20% of cases will die. Those that survive the acute stage will recover, although it may take many weeks to regain condition.
A few dogs will only develop slight fever, and sometimes diarrhoea, although they will have enlarged lymph glands.
The clinical picture is much less varied than for distemper. However, convulsions very occasionally occur, and this might confuse the diagnosis with distemper.
Blue eye is a consequence seen in some dogs where the surface of the eye shows a milky blue appearance.
- Based on the signs (acute forms) and history, your veterinary surgeon may be able to make a diagnosis.
- This may be more difficult in the mild form, as the symptoms are quite vague.
The CAV-1 virus may be detected in a commercial laboratory, following sampling of the liver or an enlarged lymph node.
On post-mortem, the liver shows characteristic changes under the microscope.
CAV-1 virus cannot be treated directly, and treatment is limited to supporting the dog during the illness.
Treatment may therefore include:
- Medication to control symptoms, such as diarrhoea, vomiting, liver failure, failure of the blood to clot.
- Nursing care to encourage the dog to eat a special liver failure diet.
- Avoidance of all exercise. Many will suffer a severe setback when taken for their first walk on apparent recovery.
- Antibiotic treatment may be used to control any secondary bacterial infections
Infected and in-contact dogs should be isolated from other susceptible dogs and hygienic precautions taken (change of clothing/targeted disinfectants etc).
Prevention is by vaccination. The canine viral hepatitis component is mostly included in the primary vaccination course given to puppies, and often in routine annual boosters. Many vaccines use the CAV-2 strain rather than the CAV-1 (viral hepatitis) strain to protect against viral hepatitis, as this also provides cross-protection for some forms of kennel cough and is less likely to cause “Blue Eye” (oedema of the surface of the eye).
Based on your pet’s specific situation, your veterinary surgeon will chose a protocol to best meet your pet’s needs.
An up-to-date vaccination is usually obligatory before going to dog shows and many kennels.
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.